Moody Lynn & Lieberson LLC Sells 12,285 Shares of Abbott Laboratories $ABT

Key Points

• Moody Lynn & Lieberson LLC sold 12,285 shares of Abbott Laboratories, reducing its holdings by 4.4%, leaving them with 267,545 shares valued at approximately $36.4 million.
• Abbott Laboratories reported earnings of $1.26 per share for the quarter, meeting consensus estimates, along with a revenue of $11.14 billion, up 7.4% year-over-year.
• The company announced a quarterly dividend of $0.59, with a record date of October 15th, leading to an annualized dividend yield of 1.8%.

Moody Lynn & Lieberson LLC decreased its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 4.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 267,545 shares of the healthcare product maker's stock after selling 12,285 shares during the period. Abbott Laboratories accounts for about 2.1% of Moody Lynn & Lieberson LLC's holdings, making the stock its 15th largest holding. Moody Lynn & Lieberson LLC's holdings in Abbott Laboratories were worth $36,389,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Brighton Jones LLC lifted its position in shares of Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock worth $5,850,000 after purchasing an additional 4,755 shares during the period. Fifth Third Wealth Advisors LLC increased its position in shares of Abbott Laboratories by 28.8% during the first quarter. Fifth Third Wealth Advisors LLC now owns 42,105 shares of the healthcare product maker's stock valued at $5,585,000 after buying an additional 9,412 shares during the period. Allied Investment Advisors LLC raised its stake in Abbott Laboratories by 4.0% in the first quarter. Allied Investment Advisors LLC now owns 90,070 shares of the healthcare product maker's stock worth $11,948,000 after buying an additional 3,489 shares in the last quarter. Abner Herrman & Brock LLC purchased a new stake in Abbott Laboratories in the first quarter worth about $18,225,000. Finally, Aletheian Wealth Advisors LLC bought a new stake in Abbott Laboratories during the 1st quarter valued at approximately $210,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Up 0.2%

NYSE:ABT opened at $133.62 on Monday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The firm has a market cap of $232.56 billion, a P/E ratio of 16.74, a P/E/G ratio of 2.53 and a beta of 0.69. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The firm has a 50-day simple moving average of $131.14 and a two-hundred day simple moving average of $131.16.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.26. The firm had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business's revenue was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be paid a $0.59 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. Abbott Laboratories's payout ratio is currently 29.57%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ABT. Morgan Stanley increased their target price on Abbott Laboratories from $127.00 to $137.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 15th. Jefferies Financial Group upgraded Abbott Laboratories from a "hold" rating to a "buy" rating and increased their price objective for the stock from $143.00 to $145.00 in a report on Friday, July 18th. Evercore ISI upped their target price on shares of Abbott Laboratories from $140.00 to $145.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 8th. Mizuho lifted their price target on shares of Abbott Laboratories from $130.00 to $140.00 and gave the company a "neutral" rating in a research report on Wednesday, July 16th. Finally, Raymond James Financial cut their price objective on shares of Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating on the stock in a report on Friday, July 18th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Abbott Laboratories presently has a consensus rating of "Moderate Buy" and an average target price of $145.22.

Insider Activity

In other news, CFO Philip P. Boudreau sold 5,550 shares of the company's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares of the company's stock, valued at $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.